<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144881</url>
  </required_header>
  <id_info>
    <org_study_id>PULSE</org_study_id>
    <nct_id>NCT04144881</nct_id>
  </id_info>
  <brief_title>Angiographic Control vs. Ischemia-driven Management of Patients Treated With PCI on Left Main With Drug-eluting Stents</brief_title>
  <acronym>PULSE</acronym>
  <official_title>Angiographic Control vs. Ischemia-driven Management of Patients Undergoing Percutaneous Revascularization of the Unprotected Left Main Coronary Artery With Second-generation Drug Eluting Stents: the PULSE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale San Luigi Gonzaga, Orbassano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Santa Croce-Carle Cuneo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AUSL Romagna Rimini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to compare a planned angiographic control (PAC) follow-up strategy vs.
      conservative management for patients treated with drug-eluting stents on unprotected left
      main artery in a prospective, randomized setting. PAC will be performed by coronary computed
      tomography (CCT), to avoid the limitations of the invasive coronary angiography which is
      usually employed to perform PAC. The superiority of a PAC-based approach will be tested on a
      hard clinical end-point such as the incidence of major adverse cardiovascular events. The
      investigators will also assess the performance of CCT as a tool to perform PAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the undefined picture surrounding the appropriateness of planned angiographic control
      (PAC) following percutaneous coronary intervention (PCI) of the unprotected left main (ULM)
      with drug-eluting stents (DES), our aim is to evaluate, in a prospective, randomized,
      setting, the potential benefits of a PAC-based strategy vs. ischemia and symptoms driven
      conservative management. The disease of the native ULM is associated with an unfavorable
      prognostic outcome, which can be at least partially reversed by revascularization.
      Significant stenosis of the stented ULM caused by in-stent restenosis (ISR), however,
      presents some peculiar pathophysiological, flow-related and shear-stress features, which
      partly makes it a distinct disease as compared to native vessel atherosclerosis. Treatment of
      ISR, moreover, is a scarcely standardized and often complex procedure; some uncertainties
      still persist regarding the best strategy to treat ISR (stent-in-stent, drug-eluting
      balloons, dilation with conventional balloons). Computed coronary tomography (CCT) can
      precisely and not-invasively assess the presence of ISR in the stented ULM, without exposing
      the patients to the risks of invasive catheterization. CCT may provide an accurate
      reconstruction of the stented vessels, exposing the patients to a limited amount of contrast
      dye (approximately, 80-100 cc) and of radiation dose (approximately, 92 mGy). CCT has a very
      high negative predictive value for ISR, thus limiting the negative impact of the
      indiscriminate execution of invasive angiography on all patients treated by PCI of the ULM.
      Only patients with relevant ISR of ULM at CCT will undergo coronary angiography to confirm
      the presence of critical stenosis, and fractional flow reserve (FFR) and/or intravascular
      ultrasound (IVUS) will be performed in dubious cases.

      An increased rate of PCI has to be taken in to account with a PAC-based approach. However,
      with the accurate, stepwise selection of the patients and the lesions amenable to PCI of our
      study protocol, based on CCT, coronary angiography and, where necessary, FFR/IVUS, the
      increased rate of PCI is not expected to bear a negative prognostic impact. Based on these
      premises, our hypothesis is that early, appropriate, detection of ULM ISR and its subsequent
      treatment may positively impact patients' survival and reduce the incidence of adverse
      cardiovascular events.

      Specific aim 1:

      Evaluation of the effectiveness and safety of a PAC-based approach to follow-up patients
      treated by PCI of the ULM with DES-II

      Specific aim 2:

      Assessment of the incidence of ISR in patients undergoing PCI of the ULM with DES-II and
      evaluation of the diagnostic accuracy of CCT in the evaluation of ISR in the stented ULM

      Specific Aim 3:

      Assessment of the prognostic implications and safety of the PCI of ISR of the ULM detected by
      PAC as compared to conservative management with revascularization driven by symptoms and
      ischemia.

      For this purpose in this prospective, randomized controlled trial (RCT), patients will be
      enrolled following the index percutaneous revascularization of ULM with DES. Patients will be
      randomized in a 1:1 fashion to PAC-based management with CCT vs.

      symptoms and ischemia driven conservative management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">October 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>18 months after the index revascularization</time_frame>
    <description>composite and mutual exclusive end point including death, cardiovascular death, myocardial infarction (MI) (excluding periprocedural MI), unstable angina (UA), stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>18 months after the index revascularization</time_frame>
    <description>target lesion revascularization including any TLR, any unplanned TLR and TLR driven by PAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>within 18 months from the index revascularization</time_frame>
    <description>death from any cause occurring during follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>within 18 months from the index revascularization</time_frame>
    <description>Any stent thrombosis (definite, probable or possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV death</measure>
    <time_frame>within 18 months from the index revascularization</time_frame>
    <description>death from cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>within 18 months from the index revascularization</time_frame>
    <description>Myocardial infarction defined as non ST elevation acute coronary syndrome (NST-ACS) or ST elevation myocardial infarction (STEMI)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AKI</measure>
    <time_frame>2 days after CCT in the experimental arm</time_frame>
    <description>Acute kidney injury (AKI) following CCT will constitute safety end-point</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function impairment</measure>
    <time_frame>18 months after the index revascularization</time_frame>
    <description>reduction of glomerular filtration rate of &gt;24% or end-stage chronic kidney disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall bleedings</measure>
    <time_frame>18 months after the index revascularization</time_frame>
    <description>Any bleeding regardless of severity, defined according to Bleeding Academic Research Consortium (BARC) criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Major bleedings</measure>
    <time_frame>18 months after the index revascularization</time_frame>
    <description>BARC bleedings type III-IV-V</description>
  </other_outcome>
  <other_outcome>
    <measure>procedural complications</measure>
    <time_frame>Index hospitalization</time_frame>
    <description>Procedural complications following each percutaneous coronary intervention (PCI): periprocedural MI defined, arterial access site complications, acute kidney injury</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Stable Chronic Angina</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Left Main Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>coronary computed tomography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conservative (ischemia-guided) management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>coronary computed tomography</intervention_name>
    <description>patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery</description>
    <arm_group_label>coronary computed tomography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with ULM disease treated by PCI with DES-II with the following inclusion criteria:

          -  Age 18-85.

          -  Glomerular filtration rate &gt; 30 ml/min Indication to percutaneous revascularization of
             ULM according to Syntax score (&lt; 33) or, in dubious cases, after Heart Team evaluation

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Refusal or inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrizio D'Ascenzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrizio D'Ascenzo, MD</last_name>
    <phone>+390116335942</phone>
    <email>fabrizio.dascenzo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luigi Gonzaga, Orbassano</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <phone>+390116336023</phone>
      <email>fabrizio.dascenzo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.</citation>
    <PMID>25173339</PMID>
  </reference>
  <reference>
    <citation>Sheiban I, Moretti C, D'Ascenzo F, Chieffo A, Taha S, Connor SO, Chandran S, de la Torre Hernández JM, Chen S, Varbella F, Omedè P, Iannaccone M, Meliga E, Kawamoto H, Montefusco A, Mervyn C, Garot P, Sin L, Gasparetto V, Abdirashid M, Cerrato E, Biondi Zoccai G, Gaita F, Escaned J, Hiddick Smith D, Lefèvre T, Colombo A. Long-Term (≥10 Years) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents. Am J Cardiol. 2016 Jul 1;118(1):32-9. doi: 10.1016/j.amjcard.2016.04.007. Epub 2016 Apr 26.</citation>
    <PMID>27209125</PMID>
  </reference>
  <reference>
    <citation>Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A, Ibrahim T, Ott I, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. Eur Heart J. 2015 Jan 7;36(2):94-9. doi: 10.1093/eurheartj/ehu383. Epub 2014 Oct 8.</citation>
    <PMID>25298237</PMID>
  </reference>
  <reference>
    <citation>Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014 Jun 24;63(24):2659-73. doi: 10.1016/j.jacc.2014.02.545. Epub 2014 Mar 13. Review.</citation>
    <PMID>24632282</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Lansky AJ, Mehran R. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2010 Nov 2;56(19):1597-604. doi: 10.1016/j.jacc.2010.08.608. Epub 2010 Oct 1.</citation>
    <PMID>20888162</PMID>
  </reference>
  <reference>
    <citation>Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, Muramatsu T, Nakamura M, Nanto S, Yokoi H, Baim DS. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of &quot;oculostenotic&quot; reintervention in patients with intermediate lesions. JACC Cardiovasc Interv. 2010 Apr;3(4):403-11. doi: 10.1016/j.jcin.2010.01.010.</citation>
    <PMID>20398868</PMID>
  </reference>
  <reference>
    <citation>Lee JY, Park DW, Kim YH, Yun SC, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ. Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. J Am Coll Cardiol. 2011 Mar 22;57(12):1349-58. doi: 10.1016/j.jacc.2010.10.041.</citation>
    <PMID>21414531</PMID>
  </reference>
  <reference>
    <citation>Biondi-Zoccai GG, Giraudi E, Moretti C, Sciuto F, Omedè P, Sillano D, Garrone P, Trevi GP, Sheiban I. Impact of routine angiographic follow-up after percutaneous coronary drug-eluting stenting for unprotected left main disease: the Turin Registry. Clin Res Cardiol. 2010 Apr;99(4):235-42. doi: 10.1007/s00392-009-0112-3. Epub 2010 Jan 3.</citation>
    <PMID>20047051</PMID>
  </reference>
  <reference>
    <citation>Valgimigli M, Chieffo A, Lefèvre T, Colombo A, Morice MC, Serruys PW. Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. EuroIntervention. 2007 Feb;2(4):435-43.</citation>
    <PMID>19755282</PMID>
  </reference>
  <reference>
    <citation>Roura G, Gomez-Lara J, Ferreiro JL, Gomez-Hospital JA, Romaguera R, Teruel LM, Carreño E, Esplugas E, Alfonso F, Cequier A. Multislice CT for assessing in-stent dimensions after left main coronary artery stenting: a comparison with three dimensional intravascular ultrasound. Heart. 2013 Aug;99(15):1106-12. doi: 10.1136/heartjnl-2013-303679. Epub 2013 May 30.</citation>
    <PMID>23723447</PMID>
  </reference>
  <reference>
    <citation>Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009 Mar 5;360(10):961-72. doi: 10.1056/NEJMoa0804626. Epub 2009 Feb 18. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.</citation>
    <PMID>19228612</PMID>
  </reference>
  <reference>
    <citation>Buchanan GL, Chieffo A, Bernelli C, Montorfano M, Carlino M, Latib A, Figini F, Giannini F, Durante A, Ielasi A, Castelli A, Colombo A. Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. EuroIntervention. 2013 Nov;9(7):809-16. doi: 10.4244/EIJV9I7A134.</citation>
    <PMID>24280157</PMID>
  </reference>
  <reference>
    <citation>Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.</citation>
    <PMID>19144937</PMID>
  </reference>
  <reference>
    <citation>D'Ascenzo F, Barbero U, Cerrato E, Lipinski MJ, Omedè P, Montefusco A, Taha S, Naganuma T, Reith S, Voros S, Latib A, Gonzalo N, Quadri G, Colombo A, Biondi-Zoccai G, Escaned J, Moretti C, Gaita F. Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: A meta-analysis of 2,581 patients and 2,807 lesions. Am Heart J. 2015 May;169(5):663-73. doi: 10.1016/j.ahj.2015.01.013. Epub 2015 Feb 21.</citation>
    <PMID>25965714</PMID>
  </reference>
  <reference>
    <citation>Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015 Jul 28;66(4):403-69. doi: 10.1016/j.jacc.2014.12.018. Epub 2014 Dec 29. Erratum in: J Am Coll Cardiol. 2015 Aug 25;66(8):982.</citation>
    <PMID>25553722</PMID>
  </reference>
  <reference>
    <citation>Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.</citation>
    <PMID>17331245</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24.</citation>
    <PMID>22922414</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999 Nov 2;100(18):1872-8.</citation>
    <PMID>10545431</PMID>
  </reference>
  <reference>
    <citation>D'Ascenzo F, Iannaccone M, Giordana F, Chieffo A, Connor SO, Napp LC, Chandran S, de la Torre Hernández JM, Chen SL, Varbella F, Omedè P, Taha S, Meliga E, Kawamoto H, Montefusco A, Chong M, Garot P, Sin L, Gasparetto V, Abdirashid M, Cerrato E, Biondi-Zoccai G, Gaita F, Escaned J, Hiddick Smith D, Lefèvre T, Colombo A, Sheiban I, Moretti C. Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: A propensity matched analysis. Int J Cardiol. 2016 May 15;211:37-42. doi: 10.1016/j.ijcard.2016.02.136. Epub 2016 Mar 3.</citation>
    <PMID>26970964</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Fabrizio D'Ascenzo</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

